Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep ... for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx ...

The patient had marked pitting edema in the right lower leg. Early scarring was present on the knee, right medial leg, and right medial malleolus at the sites of rod and screw insertion.

MediWound (MDWD) shares ended the last trading session 8.5% higher at $19.83. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Substances that increase the "stickiness" of adhesives, called bonding agents or tackifiers, are used to increase cohesive strength of adhesives; an example is the use to enhance wound closure ...

However, the absorptive aspect of polyurethane foams makes them inappropriate for dry or eschar-covered wounds and arterial ulcers. Hydrocolloids such as pectin, gelatin, and carboxymethyl cellulose ...